Quinn MA - Search Results

1

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.

Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, Thompson EW, Findlay JK, Ahmed N. Abubaker K, et al. Among authors: quinn ma. Mol Cancer. 2013 Mar 27;12:24. doi: 10.1186/1476-4598-12-24. Mol Cancer. 2013. PMID: 23537295 Free PMC article.

2

Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.

Ahmed N, Abubaker K, Findlay J, Quinn M. Ahmed N, et al. Curr Cancer Drug Targets. 2010 May;10(3):268-78. doi: 10.2174/156800910791190175. Curr Cancer Drug Targets. 2010. PMID: 20370691 Review.

3

Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.

Ahmed N, Abubaker K, Findlay J, Quinn M. Ahmed N, et al. J Cell Biochem. 2013 Jan;114(1):21-34. doi: 10.1002/jcb.24317. J Cell Biochem. 2013. PMID: 22887554 Review.

4

Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm.

Ahmed N, Thompson EW, Quinn MA. Ahmed N, et al. Among authors: quinn ma. J Cell Physiol. 2007 Dec;213(3):581-8. doi: 10.1002/jcp.21240. J Cell Physiol. 2007. PMID: 17708542 Review.

5

Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.

Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK, Ahmed N. Latifi A, et al. Among authors: quinn ma. J Cell Biochem. 2011 Oct;112(10):2850-64. doi: 10.1002/jcb.23199. J Cell Biochem. 2011. PMID: 21618587

6

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N. Latifi A, et al. Among authors: quinn ma. PLoS One. 2012;7(10):e46858. doi: 10.1371/journal.pone.0046858. Epub 2012 Oct 8. PLoS One. 2012. PMID: 23056490 Free PMC article.

7

Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.

Abubaker K, Luwor RB, Escalona R, McNally O, Quinn MA, Thompson EW, Findlay JK, Ahmed N. Abubaker K, et al. Among authors: quinn ma. Front Oncol. 2014 Apr 9;4:75. doi: 10.3389/fonc.2014.00075. eCollection 2014. Front Oncol. 2014. PMID: 24782986 Free PMC article.

8

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.

Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N. Abubaker K, et al. Among authors: quinn ma. BMC Cancer. 2014 May 6;14:317. doi: 10.1186/1471-2407-14-317. BMC Cancer. 2014. PMID: 24886434 Free PMC article.

9

A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.

Samardzija C, Luwor RB, Volchek M, Quinn MA, Findlay JK, Ahmed N. Samardzija C, et al. Among authors: quinn ma. Mol Cancer. 2015 Aug 11;14:152. doi: 10.1186/s12943-015-0417-y. Mol Cancer. 2015. PMID: 26260289 Free PMC article.

10

Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.

Samardzija C, Luwor RB, Quinn MA, Kannourakis G, Findlay JK, Ahmed N. Samardzija C, et al. Among authors: quinn ma. BMC Cancer. 2016 Jul 8;16:432. doi: 10.1186/s12885-016-2458-z. BMC Cancer. 2016. PMID: 27390927 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

275 results

Search Page

Filters